NasdaqGM - Delayed Quote • USD
Intellia Therapeutics, Inc. (NTLA)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 22 | 22 | 25 | 25 |
| Avg. Estimate | -1.38 | -1.29 | -5.61 | -5.49 |
| Low Estimate | -1.58 | -1.68 | -7.07 | -7.59 |
| High Estimate | -1.02 | -0.98 | -4.55 | -1.72 |
| Year Ago EPS | -1.17 | -1.4 | -5.42 | -5.61 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 19 | 26 | 23 |
| Avg. Estimate | 11.5M | 20.29M | 50.72M | 54.73M |
| Low Estimate | -- | 3M | 9M | -- |
| High Estimate | 34.17M | 44M | 102.5M | 210M |
| Year Ago Sales | -- | 12.08M | 36.27M | 50.72M |
| Sales Growth (year/est) | -- | 68.00% | 39.80% | 7.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.4 | -1.32 | -1.5 | -1.45 |
| EPS Actual | -1.17 | -1.4 | -1.38 | -1.46 |
| Difference | 0.23 | -0.08 | 0.12 | -0.01 |
| Surprise % | 16.40% | -6.10% | 8.00% | -0.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.38 | -1.29 | -5.61 | -5.49 |
| 7 Days Ago | -1.38 | -1.29 | -5.61 | -5.49 |
| 30 Days Ago | -1.38 | -1.29 | -5.61 | -5.49 |
| 60 Days Ago | -1.41 | -1.32 | -5.7 | -5.88 |
| 90 Days Ago | -1.43 | -1.37 | -5.86 | -6.06 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | NTLA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -17.90% | -- | -- | 2.60% |
| Next Qtr. | 7.90% | -- | -- | 13.40% |
| Current Year | -3.50% | -- | -- | 5.20% |
| Next Year | 2.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 30.00% | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Wedbush: Neutral to Neutral | 4/23/2024 |
| Downgrade | Goldman Sachs: Buy to Neutral | 2/23/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 2/23/2024 |
| Initiated | Wolfe Research: Peer Perform | 2/15/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 11/13/2023 |
| Maintains | Morgan Stanley: Overweight to Overweight | 11/13/2023 |
Related Tickers
BEAM Beam Therapeutics Inc.
21.60
-5.01%
EDIT Editas Medicine, Inc.
5.22
-2.43%
CRSP CRISPR Therapeutics AG
53.73
-3.45%
CRBU Caribou Biosciences, Inc.
3.7600
-2.34%
VERV Verve Therapeutics, Inc.
6.22
-5.47%
PRME Prime Medicine, Inc.
4.3000
-8.51%
DNA Ginkgo Bioworks Holdings, Inc.
0.7777
-8.05%
RXRX Recursion Pharmaceuticals, Inc.
7.84
-1.26%
VRTX Vertex Pharmaceuticals Incorporated
397.70
-0.76%
BLUE bluebird bio, Inc.
0.9125
-1.13%